Company Encyclopedia
View More
name
Regulus Therap
RGLS.US
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc.
1.935 T
RGLS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

    Novartis AG has completed its acquisition of Regulus Therapeutics for $1.7 billion, confirming the deal on June 23. Following the acquisition, Regulus shares have ceased trading on NASDAQ, and it is now a fully owned subsidiary of Novartis. This move positions Novartis as one of the top European stocks to invest in.

    MSN·
    DE
    NOT
    0.00%
    US
    RGLS
    0.00%
    US
    NVS
    +0.22%
    MSN·
    DE
    NOT
    0.00%
    US
    RGLS
    0.00%
    US
    NVS
    +0.22%

    Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary

    Novartis AG has acquired Regulus Therapeutics Inc., making it a wholly owned subsidiary. This acquisition aims to enhance Novartis' clinical development for a potential treatment for autosomal dominant polycystic kidney disease (ADPKD). The merger was finalized through a tender offer, providing cash and contingent value rights to shareholders. This strategic move strengthens Novartis' renal disease pipeline, leveraging Regulus' expertise and promising trial results for farabursen, an investigational treatment for ADPKD.

    Reuters·
    US
    RGLS
    0.00%
    DE
    NOT
    0.00%
    Reuters·
    US
    RGLS
    0.00%
    DE
    NOT
    0.00%

    Novartis' tender offer to acquire all shares of Regulus for $7.00 in cash per share and one contingent value right has expired.

    Novartis' tender offer to acquire all shares of Regulus Therapeutics Inc. for $7.00 in cash per share, along with one contingent value right, has expired. The offer, executed by Redwood Merger Sub Inc., a wholly owned subsidiary of Novartis, concluded on June 24, 2025, at 11:59 p.m. New York City Time. Each CVR entitles the holder to an additional $7.00 contingent payment upon achieving a regulatory milestone.

    Unusual Whales·
    US
    RGLS
    0.00%
    Unusual Whales·
    US
    RGLS
    0.00%

    Novartis' Tender Offer for Regulus Therapeutics Expires with 74.49% Shareholder Acceptance

    Novartis AG's tender offer to acquire Regulus Therapeutics Inc. has expired, with 74.49% of shares tendered. The offer was for $7.00 per share in cash, plus a contingent value right for an additional $7.00 based on a regulatory milestone. The transaction is set to close on June 25, 2025, following the acceptance of the tendered shares. This announcement was published via GlobeNewswire.

    Reuters·
    US
    NVS
    +0.22%
    US
    RGLS
    0.00%
    Reuters·
    US
    NVS
    +0.22%
    US
    RGLS
    0.00%

    Novartis: HSR Waiting Period For Regulus Acquisition Has Ended

    Unusual Whales·
    US
    RGLS
    0.00%
    Unusual Whales·
    US
    RGLS
    0.00%
    © 2025 Longbridge｜Disclaimer